ovarian cancer
Conditions
Interventions
Group 1:Sufentanil 0.04 µg·kg-1·h-1
Group 2:Butorphanol 3.0ug·kg-1·h-1
Group 3:Butorphanol 3.5ug·kg-1·h-1
Group 4:Butorphanol 4.0ug·kg-1·h-1
Sponsors
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. ASA level I - III; 2. Patient compliance is good; 3. Ovarian cancer confirmed by postoperative pathologic diagnosis and receive cytoreductive surgery; 4. No history of related drug allergies; 5. FIGO classification I-III; 6. Age 18-65 years old.
Exclusion criteria
Exclusion criteria: 1. Patients with multiple chronic diseases who cannot tolerate surgical anesthesia; 2. Severe heart, lung, and kidney dysfunction; 3. Coagulation dysfunction; 4. Individuals with drug allergies and contraindications; 5. Patients with severe sequelae of neurological disorders; 6. Patients with advanced malignant tumors; 7. Previous or recent history of taking opioid drugs; 8. Recent new infections or immune system diseases; 9. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analogue Scale/Score,; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reactions;Rescue analgesia;CD4+ T lymphocyte;CD8+ lymphocyte;CA-125;HE4;Inflammatory factor; | — |
Countries
China
Contacts
Public ContactWei Zhang
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Outcome results
None listed